Երկիր: Իռլանդիա
Լեզու: անգլերեն
Աղբյուրը: HPRA (Health Products Regulatory Authority)
FERROUS FUMARATE SODIUM ASCORBATE NICOTINAMIDE THIAMINE MONONITRATE RIBOFLAVIN PYRIDOXINE HYDROCHLORIDE FOLIC ACID
Galen Limited
FERROUS FUMARATE SODIUM ASCORBATE NICOTINAMIDE THIAMINE MONONITRATE RIBOFLAVIN PYRIDOXINE HYDROCHLORIDE FOLIC ACID
%v/v
Capsule
Withdrawn
2007-04-23
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Givitol Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substances For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard Size No. 2, opaque, hard gelatin capsules having a maroon body, and scarlet cap, imprinted with the name ‘Givitol’ on both sections, and containing a brown and yellow coloured powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Givitol is indicated for the prophylaxis of iron and folic acid deficiencies after the first 13 weeks of pregnancy. Givitol is indicated particularly when inadequate diet calls for supplementary vitamins B and C. 4.2 POSOLOGY AND METHOD OF ADMINSTRATION For oral administration. For prophylaxis:1 capsule daily. 4.3 CONTRAINDICATIONS Contraindicated in patients with megaloblastic anaemia due to vitamin B deficiency and in patients with a known hypersensitivity to the product or its ingredients. Givitol is also contrainidicated in patients with haemochromatosis and iron overload syndrome. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Givitol is intended only for the prevention of iron and folic acid deficiencies in pregnancy; the dose of folic acid provided is inadequate for the treatment of megaloblastic anaemias. The development of anaemia despite prophylaxis with Givitol requires further investigation and appropriate therapy. Ferrous Fumarate 305.00 mg (equivalent to 100mg of elemental iron) Sodium Ascorbate 56.0 mg Nicotinamide 10.0 mg Thiamine Mononitrate 2.0 mg Riboflavin 2.0 mg Pyridoxine Hydrochloride 4.0 mg Folic Acid 0.50 mg 12 IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 19/06/2006_ _CRN 2024548_ _page number: 1_ Use with caution in patients with haemoglob Կարդացեք ամբողջական փաստաթուղթը